The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...
PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, ...
SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...
DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...
POTOMAC, MD, USA I November 25, 2024 I IGC Pharma, Inc. (NYSE American: IGC) (“IGC Pharma” or the “Company”) today announced additional interim data from its ongoing Phase 2 clinical trial evaluating ...
NEW HAVEN, CT, USA I November 25, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
SÖDERTÄLJE, Sweden I6, 2024 I Anocca AB, a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, announces the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback